Shattuck Labs, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for STTK, updated each market day.
STTK AI Sentiment
AI predicts Shattuck Labs, Inc. Common Stock stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Shattuck Labs, Inc. Common Stock
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
Sector
Exchange
Market Cap
$559,305,223
Cap Tier
Employees
40
Headquarters
AUSTIN, TX
Listed Since
Oct. 9, 2020
Website
STTK Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
STTK Volatility
Shattuck Labs, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
